Eli Lilly and Alchemab Therapeutics have partnered to develop new therapies for amyotrophic lateral sclerosis (ALS). The ...

The phase 3 POETYK PsA-1 trial evaluated the drug in patients who were not previously treated with a biologic ...

In its latest update of AXS-05, Axsome reported that the 295-patient phase 3 ACCORD-2 trial met its primary endpoint, with ...

Durbin is one of the world’s leading specialist medical suppliers. Established nearly 50 years ago in 1963, we source and distribute pharmaceuticals, medical equipment and consumable supplies to ...

Gower is recognised as one of the world’s leading publishers of specialist business and management books and resources. Our publishing programme covers many of the main business processes and ...

Blue Latitude Health is a creative marketing consultancy. Founded in 2003, our combination of heritage, approach and capability gives us a unique perspective in healthcare marketing. We’re ideally ...

Evoke Kyne is an award-winning communications agency that harnesses insight, experience and creativity to advance health and wellbeing around the world. We were founded on the belief that ...

Step into the future of medical education with our exclusive webinar series from February 25-26, designed specifically for Pharma leaders. This transformative series will showcase the 2025 Pharma ...

AstraZeneca’s Tagrisso (osimertinib) has been approved by the European Commission (EC) to treat a new subset of lung cancer patients. The epidermal growth factor receptor (EGFR)-tyrosine kinase ...

Pfizer’s Braftovi (encorafenib) regimen has been granted accelerated approval by the US Food and Drug Administration (FDA) to treat metastatic colorectal cancer (mCRC). The drug has been authorised ...

Is your medical education strategy reaching the right HCPs in the formats they prefer? Discover actionable insights to elevate the impact of your medical education efforts in the latest Medical ...

For many years the pharma sector has been vocal in its commitment to a ‘patient-focused’ approach. As a result, there does seem to be more attention on the patient across med affairs, marketing and ...